Cytovance Biologics, a leading US-based contract development and manufacturing organization (CDMO) serving the biopharmaceutical industry, today announced the expansion of its upstream process ...

Many recombinant viral vectors for expression of ectopic antigens mimic a natural infection and can induce a robust immune response against certain pathogens and tumors. Host-restricted poxviruses and ...

Downstream purification continues to pressure the biopharmaceutical manufacturing industry from a capacity standpoint, with recent increases in upstream yield and titers overcoming the relatively slow ...

Scaling a viral vector process from benchtop to clinical supply isn't a bigger version of monoclonal antibody (mAb) manufacturing, but an entirely different analytical challenge. Cell and gene therapy ...